ArticleTranslational cancer research2026

Trastuzumab deruxtecan plus pertuzumab in first-line HER2-positive advanced/metastatic breast cancer.

Sara M Tolaney et al.PubMed ↗Full text ↗Publisher ↗

No numbers read from the abstract.